- Molecular NameCeftibuten
- SynonymNA
- Weight410.431
- Drugbank_IDDB01415
- ACS_NO97519-39-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.74
- pka2.3; 3.2; 4.5
- LogD (pH=7, predicted)-5.71
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.39
- LogSw (predicted, AB/LogsW2.0)16.32
- Sw (mg/ml) (predicted, ACD/Labs)1.03
- No.of HBond Donors5
- No.of HBond Acceptors10
- No.of Rotatable Bonds6
- TPSA216.46
- StatusFDA approved
- AdministrationN/A
- PharmacologyA third-generation cephalosporin antibiotic.
- Absorption_valueN/A
- Absorption (description)Ceftibuten is rapidly absorbed after oral administration.
- Caco_2N/A
- Bioavailability82.5
- Protein binding65.0
- Volume of distribution (VD)0.21 L/kg and 0.5 L/kg for capsules and suspension, respectively.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- Metabollsmstudy with radiolabeled ceftibuten administered to 6 healthy adult male volunteers demonstrated that cis -ceftibuten is the predominant component in both plasma and urine. About 10% of ceftibuten is converted to the trans -isomer is approximately 1 / 8 as antimicrobially potent as the cis -isomer.
- Half life7.1 hours for patients with renal insufficiency
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe adverse effects considered drug-related and led to discontinuation of ceftibuten administration incude primarily gastrointestinal disturbances, usually diarrhea, vomiting, or nausea (2% patients). 0.3% patients were discontinued due to rash or pruritus thought related to ceftibuten administration.
- LD50 (rat)N/A
- LD50 (mouse)N/A